The study is designed as an open, non-randomized, phase IV cohort study in which the mRNA vaccine Comirnaty will be given in two doses. Analyses will be performed on blood and saliva, investigating humoral and cellular vaccine responses. Occurence of local or systemic reactogenicity will be evaluated, as well as adverse events. The study will include persons with primary or secondary immunosuppressive disorders, as well as immunocompetent persons, with the aim of investigating if the immune responses after given Comirnaty mRNA vaccine against COVID-19.
In this study with 450 patients with primary or secondary immunosuppressive disorders
(patients with primary immunodeficiency, HIV infected patients, patients with allogenic stem
cell transplantation/CAR T cell treated, solid organ transplanted, and patients with chronic
lymphatic leukemia) from Karolinska University Hospital, and healthy controls of 90
individuals for comparison, we will investigate the safety and the immune responses after
mRNA vaccination with Comirnaty after two doses, under 6 months of time for each participant.
The study is In collaboration with research groups at Karolinska Institutet and SciLifeLab,
with planned in-depth detailed analyses of antibody responses as well as cellular responses.
The study has obtained permission from Swedish Medical Agency and Swedish Ethical Review
Authority.
Biological: Comirnaty (COVID-19, mRNA vaccine)
Comirnaty will be administered two times, one at Day 0 and the second dose at Day 21.
Other Name: Array
Inclusion Criteria:
1. Individuals ≥18 years old
2a. In the opinion of the investigator, individuals with immunosuppressive disease who meet
one of the following criteria:
- Primary immunodeficiency
- Human immunodeficiency virus (HIV)-infection
- Allogeneic stem cell transplantation / Chimeric antigen receptor (CAR T cell) therapy
- Solid organ transplant
- Chronic lymphatic leukemia
or
2b. In the opinion of the investigator, individuals without immunosuppressive disease or
treatment without significant co-morbidity
3. Provision of signed informed consent to participate in the study
Exclusion Criteria:
1. Previous or ongoing Coronavirus Disease-19 (COVID-19).
2. Coagulation disorders, other conditions associated with prolonged bleeding time or
anticoagulant treatments, which according to the investigator contraindicate
intramuscular injection. Conditions which can be corrected with measures such as
platelet concentrate treatments, coagulation factors or other measures for people
responsible for anticoagulants are not exclusion criteria.
3. Planned to receive another vaccine within 14 days before the first dose of the study
vaccine, or during the period from the first dose of the study vaccine up to 14 days
after the second dose of the study vaccine, and vaccination with another vaccine which
in the investigator's opinion cannot be planned outside these time periods
4. Pregnancy or breast feeding.
5. Hypersensitivity to the active substance or to any of the excipients contained in the
vaccine
6. Individuals who cannot understand the informed consent.
7. Individuals who for other reasons are considered by investigators as not suitable for
inclusion
Karolinska University Hospital
Stockholm, Huddinge, Sweden
Soo Aleman, MD, PhD, Principal Investigator
Karolinska University Hospital, ME Infectious Diseases